Neuroblastoma - Pipeline Review, H2 2017 - Product Image

Neuroblastoma - Pipeline Review, H2 2017

  • ID: 4429825
  • Report
  • 506 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Actuate Therapeutics Inc
  • BioLineRx Ltd
  • Cielo Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Loxo Oncology Inc
  • OGD2 Pharma SAS
  • MORE
Neuroblastoma - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Neuroblastoma - Pipeline Review, H2 2017, provides an overview of the Neuroblastoma (Oncology) pipeline landscape.

Neuroblastoma is the cancer of the nerve tissues and neural crest cells of adrenal glands, neck, chest or spinal cord, occurring predominantly in children. It usually begins in the adrenal glands further spreading to other parts of the body. The predisposing factors involved in neuroblastoma include genetic conditions. Symptoms include lump in abdomen or chest, weakness, bone pain, breathing problems, dark circles around the eyes and difficulty in movement. The condition may be diagnosed by X-ray imaging, CT scan, MRI, biopsy, urine test, etc. It may be controlled by chemotherapy, radiation therapy, stem cell transplants and medication such as monoclonal antibody regimens.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Neuroblastoma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Neuroblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neuroblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 27, 20, 1, 48, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 6, 5, 13 and 3 molecules, respectively.

Neuroblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Neuroblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neuroblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neuroblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neuroblastoma (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neuroblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neuroblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Actuate Therapeutics Inc
  • BioLineRx Ltd
  • Cielo Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • Loxo Oncology Inc
  • OGD2 Pharma SAS
  • MORE
Introduction

Neuroblastoma - Overview

Neuroblastoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neuroblastoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neuroblastoma - Companies Involved in Therapeutics Development

Ability Pharmaceuticals SL

Actuate Therapeutics Inc

Advanced Accelerator Applications SA

Alissa Pharma

Ampio Pharmaceuticals Inc

APAvadis Biotechnologies Srl

APEIRON Biologics AG

AstraZeneca Plc

Autolus Ltd

Bayer AG

Bellicum Pharmaceuticals Inc

Bexion Pharmaceuticals LLC

BioLineRx Ltd

Biotec Pharmacon ASA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Cancer Prevention Pharmaceuticals Inc

Cebiotex SL

Celgene Corp

Celldex Therapeutics Inc

Cielo Therapeutics Inc

Cleveland BioLabs Inc

CorMedix Inc

Curis Inc

Cyclacel Pharmaceuticals Inc

DEKK-TEC Inc

EnGeneIC Ltd

Epizyme Inc

Errant Gene Therapeutics LLC

F. Hoffmann-La Roche Ltd

GlaxoSmithKline Plc

Green Cross Cell Corp

Ignyta Inc

Ipsen SA

Juno Therapeutics Inc

Lindis Biotech GmbH

Loxo Oncology Inc

MabVax Therapeutics Holdings Inc

MacroGenics Inc

MediaPharma SRL

Merck & Co Inc

Morphogenesis Inc

Novartis AG

Novogen Ltd

OGD2 Pharma SAS

Pfizer Inc

Phylogica Ltd

Progenics Pharmaceuticals Inc

Recombio SL

Ribomic Inc

Sapience Therapeutics Inc

Sareum Holdings Plc

Sierra Oncology Inc

Sorrento Therapeutics Inc

Syros Pharmaceuticals Inc

Tiltan Pharma Ltd

Neuroblastoma - Drug Profiles

1-B7 - Drug Profile

31-F9 - Drug Profile

9-ING41 - Drug Profile

abexinostat hydrochloride - Drug Profile

ABTL-0812 - Drug Profile

ACY-1035 - Drug Profile

ACY-957 - Drug Profile

afatinib dimaleate - Drug Profile

ALKCAR-15 - Drug Profile

ALKCAR-48 - Drug Profile

ALKCAR-53 - Drug Profile

ALKCAR-58 - Drug Profile

AMB-8LK - Drug Profile

AMXT-1501 + eflornithine hydrochloride - Drug Profile

APN-301 - Drug Profile

AT-69 - Drug Profile

BACPT-DP - Drug Profile

bevacizumab - Drug Profile

BGA-002 - Drug Profile

Bispecific Monoclonal Antibody to Target GD2 and CD3 for Oncology - Drug Profile

BL-8040 - Drug Profile

BPX-701 - Drug Profile

BXQ-350 - Drug Profile

CBL-0137 - Drug Profile

CCT-244747 - Drug Profile

CCT-68127 - Drug Profile

CEB-01 - Drug Profile

Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile

Cellular Immunotherapy for Neuroblastoma - Drug Profile

Cellular Immunotherapy for Neuroblastoma - Drug Profile

Cellular Immunotherapy for Oncology - Drug Profile

Cellular Immunotherapy to Target CD3 and GD2 for Neuroblastoma - Drug Profile

Cellular Immunotherapy to Target GD2 and CD56 for Solid Tumors - Drug Profile

Cellular Immunotherapy to Target GD2 for Melanoma and Neuroblastoma - Drug Profile

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile

Cellular Immunotherapy to Target GD2 for Neuroblastoma - Drug Profile

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile

Celyvir - Drug Profile

ceritinib - Drug Profile

CG-1521 - Drug Profile

CMD-501 - Drug Profile

crizotinib - Drug Profile

CYC-065 - Drug Profile

dactolisib tosylate - Drug Profile

danusertib - Drug Profile

dinutuximab beta - Drug Profile

DS-1647 - Drug Profile

Edotreotide Labeled Yttrium 90 - Drug Profile

eflornithine - Drug Profile

eh-8B6 - Drug Profile

enoblituzumab - Drug Profile

ensartinib - Drug Profile

entrectinib - Drug Profile

fimepinostat - Drug Profile

FSEC - Drug Profile

Gene Therapy to Activate GAS1 for Oncology - Drug Profile

GSK-525762 - Drug Profile

HSV-1716 - Drug Profile

ICA-1 - Drug Profile

Immuncell-LC - Drug Profile

ImmuneFx - Drug Profile

iobenguane sulfate I 131 - Drug Profile

ipilimumab + nivolumab - Drug Profile

irinotecan hydrochloride - Drug Profile

irinotecan hydrochloride + TBio-02 - Drug Profile

JCAR-023 - Drug Profile

Kid EDV - Drug Profile

KOS-1803 - Drug Profile

KTN-0125TEI - Drug Profile

larotrectinib - Drug Profile

lorlatinib - Drug Profile

lutetium Lu 177 dotatate - Drug Profile

M-606 - Drug Profile

M-7085 - Drug Profile

Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile

Monoclonal Antibody Conjugate to Target CD56 for Neuroblastoma - Drug Profile

Monoclonal Antibody Conjugates to Target Glypican-2 for Neuroblastoma - Drug Profile

Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile

Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile

MPTEM-1ADC - Drug Profile

NCE-001 - Drug Profile

nifurtimox - Drug Profile

OGD-201 - Drug Profile

olaparib - Drug Profile

Oncolytic Virus for Neuroblastoma - Drug Profile

Oncolytic Virus for Neuroblastoma - Drug Profile

Oncolytic Virus to Activate TIMP3 for Neuroblastoma and Malignant Peripheral Nerve Sheath Tumor - Drug Profile

ORP-008 - Drug Profile

paclitaxel albumin bound - Drug Profile

pazopanib hydrochloride - Drug Profile

pembrolizumab - Drug Profile

Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile

racotumomab - Drug Profile

RBM-001 - Drug Profile

ribociclib succinate - Drug Profile

RNAi Oligonucleotides for Neuroblastoma - Drug Profile

RSF-701 - Drug Profile

SAR-020106 - Drug Profile

SAR-4 - Drug Profile

selumetinib sulfate - Drug Profile

SF-1126 - Drug Profile

SF-2523 - Drug Profile

Small Molecules 3 for Oncology - Drug Profile

Small Molecules to Inhibit ALK for Oncology - Drug Profile

Soluble Beta Glucan - Drug Profile

SRA-737 - Drug Profile

ST-36 - Drug Profile

SY-1365 - Drug Profile

Synthetic Peptide to Inhibit C-Myc for Oncology - Drug Profile

Synthetic Peptide to Inhibit N-Myc for Oncology - Drug Profile

taurolidine - Drug Profile

tazemetostat - Drug Profile

TL-118 - Drug Profile

TR-100 - Drug Profile

TRBS-07 - Drug Profile

Trilexium - Drug Profile

Vaccine for Neuroblastoma - Drug Profile

Vaccine for Neuroblastoma - Drug Profile

Vaccine for Neuroblastoma - Drug Profile

Vaccine to Target GD2 and GD3 for Neuroblastoma - Drug Profile

Vaccine to Target WT1 for Oncology - Drug Profile

vemurafenib - Drug Profile

VIMO-001 - Drug Profile

Neuroblastoma - Dormant Projects

Neuroblastoma - Discontinued Products

Neuroblastoma - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Neuroblastoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Universities/Institutes, H2 2017

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Neuroblastoma - Pipeline by Ability Pharmaceuticals SL, H2 2017

Neuroblastoma - Pipeline by Actuate Therapeutics Inc, H2 2017

Neuroblastoma - Pipeline by Advanced Accelerator Applications SA, H2 2017

Neuroblastoma - Pipeline by Alissa Pharma, H2 2017

Neuroblastoma - Pipeline by Ampio Pharmaceuticals Inc, H2 2017

Neuroblastoma - Pipeline by APAvadis Biotechnologies Srl, H2 2017

Neuroblastoma - Pipeline by APEIRON Biologics AG, H2 2017

Neuroblastoma - Pipeline by AstraZeneca Plc, H2 2017

Neuroblastoma - Pipeline by Autolus Ltd, H2 2017

Neuroblastoma - Pipeline by Bayer AG, H2 2017

Neuroblastoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2017

Neuroblastoma - Pipeline by Bexion Pharmaceuticals LLC, H2 2017

Neuroblastoma - Pipeline by BioLineRx Ltd, H2 2017

Neuroblastoma - Pipeline by Biotec Pharmacon ASA, H2 2017

Neuroblastoma - Pipeline by Boehringer Ingelheim GmbH, H2 2017

Neuroblastoma - Pipeline by Bristol-Myers Squibb Co, H2 2017

Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals Inc, H2 2017

Neuroblastoma - Pipeline by Cebiotex SL, H2 2017

Neuroblastoma - Pipeline by Celgene Corp, H2 2017

Neuroblastoma - Pipeline by Celldex Therapeutics Inc, H2 2017

Neuroblastoma - Pipeline by Cielo Therapeutics Inc, H2 2017

Neuroblastoma - Pipeline by Cleveland BioLabs Inc, H2 2017

Neuroblastoma - Pipeline by CorMedix Inc, H2 2017

Neuroblastoma - Pipeline by Curis Inc, H2 2017

Neuroblastoma - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017

Neuroblastoma - Pipeline by DEKK-TEC Inc, H2 2017

Neuroblastoma - Pipeline by EnGeneIC Ltd, H2 2017

Neuroblastoma - Pipeline by Epizyme Inc, H2 2017

Neuroblastoma - Pipeline by Errant Gene Therapeutics LLC, H2 2017

Neuroblastoma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Neuroblastoma - Pipeline by GlaxoSmithKline Plc, H2 2017

Neuroblastoma - Pipeline by Green Cross Cell Corp, H2 2017

Neuroblastoma - Pipeline by Ignyta Inc, H2 2017

Neuroblastoma - Pipeline by Ipsen SA, H2 2017

Neuroblastoma - Pipeline by Juno Therapeutics Inc, H2 2017

Neuroblastoma - Pipeline by Lindis Biotech GmbH, H2 2017

Neuroblastoma - Pipeline by Loxo Oncology Inc, H2 2017

Neuroblastoma - Pipeline by MabVax Therapeutics Holdings Inc, H2 2017

Neuroblastoma - Pipeline by MacroGenics Inc, H2 2017

Neuroblastoma - Pipeline by MediaPharma SRL, H2 2017

Neuroblastoma - Pipeline by Merck & Co Inc, H2 2017

Neuroblastoma - Pipeline by Morphogenesis Inc, H2 2017

Neuroblastoma - Pipeline by Novartis AG, H2 2017

Neuroblastoma - Pipeline by Novogen Ltd, H2 2017

Neuroblastoma - Pipeline by OGD2 Pharma SAS, H2 2017

Neuroblastoma - Pipeline by Pfizer Inc, H2 2017

Neuroblastoma - Pipeline by Phylogica Ltd, H2 2017

Neuroblastoma - Pipeline by Progenics Pharmaceuticals Inc, H2 2017

Neuroblastoma - Pipeline by Recombio SL, H2 2017

Neuroblastoma - Pipeline by Ribomic Inc, H2 2017

Neuroblastoma - Pipeline by Sapience Therapeutics Inc, H2 2017

Neuroblastoma - Pipeline by Sareum Holdings Plc, H2 2017

Neuroblastoma - Pipeline by Sierra Oncology Inc, H2 2017

Neuroblastoma - Pipeline by Sorrento Therapeutics Inc, H2 2017

Neuroblastoma - Pipeline by Syros Pharmaceuticals Inc, H2 2017

Neuroblastoma - Pipeline by Tiltan Pharma Ltd, H2 2017

Neuroblastoma - Dormant Projects, H2 2017

Neuroblastoma - Dormant Projects, H2 2017 (Contd..1), H2 2017

Neuroblastoma - Dormant Projects, H2 2017 (Contd..2), H2 2017

Neuroblastoma - Discontinued Products, H2 2017

List of Figures

Number of Products under Development for Neuroblastoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Ability Pharmaceuticals SL
  • Actuate Therapeutics Inc
  • Advanced Accelerator Applications SA
  • Alissa Pharma
  • Ampio Pharmaceuticals Inc
  • APAvadis Biotechnologies Srl
  • APEIRON Biologics AG
  • AstraZeneca Plc
  • Autolus Ltd
  • Bayer AG
  • Bellicum Pharmaceuticals Inc
  • Bexion Pharmaceuticals LLC
  • BioLineRx Ltd
  • Biotec Pharmacon ASA
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cancer Prevention Pharmaceuticals Inc
  • Cebiotex SL
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cielo Therapeutics Inc
  • Cleveland BioLabs Inc
  • CorMedix Inc
  • Curis Inc
  • Cyclacel Pharmaceuticals Inc
  • DEKK-TEC Inc
  • EnGeneIC Ltd
  • Epizyme Inc
  • Errant Gene Therapeutics LLC
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Green Cross Cell Corp
  • Ignyta Inc
  • Ipsen SA
  • Juno Therapeutics Inc
  • Lindis Biotech GmbH
  • Loxo Oncology Inc
  • MabVax Therapeutics Holdings Inc
  • MacroGenics Inc
  • MediaPharma SRL
  • Merck & Co Inc
  • Morphogenesis Inc
  • Novartis AG
  • Novogen Ltd
  • OGD2 Pharma SAS
  • Pfizer Inc
  • Phylogica Ltd
  • Progenics Pharmaceuticals Inc
  • Recombio SL
  • Ribomic Inc
  • Sapience Therapeutics Inc
  • Sareum Holdings Plc
  • Sierra Oncology Inc
  • Sorrento Therapeutics Inc
  • Syros Pharmaceuticals Inc
  • Tiltan Pharma Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll